The Makeblock mBot2 Rover Kit is an educational robotics platform designed to introduce learners to STEM concepts through hands-on building and coding. As outlined by Core Electronics, the kit ...

HINGHAM, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, is continuing to generate ...

Robotics is a fascinating field that has come a long way in recent years. What was once cutting-edge and prohibitively expensive for consumer-grade projects has rapidly become accessible to the hobby ...

Fintel reports that on October 15, 2025, HC Wainwright & Co. reiterated coverage of Microbot Medical (NasdaqCM:MBOT) with a Buy recommendation. Analyst Price Forecast Suggests 325.00% Upside As of ...

HINGHAM, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic System, announced it has been approved to receive a ...

HINGHAM, Mass. - Microbot Medical Inc. (NASDAQ:MBOT), a developer of the LIBERTY Endovascular Robotic System, is actively preparing for the system’s anticipated U.S. launch projected for the third ...

MICROBOT MEDICAL ($MBOT) posted quarterly earnings results on Tuesday, March 25th. The company reported earnings of -$0.20 per share, missing estimates of -$0.18 by ...

MICROBOT MEDICAL ($MBOT) is expected to release its quarterly earnings data on Tuesday, March 25th after market close, per Finnhub. Analysts are expecting revenue of ...

Mr. Paul Mullen Most Recently Served as the Director of Sales at Inari Medical which was Acquired by Stryker Corporation Earlier This Year This Appointment Represents the Company's First Commercial ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Microbot Medical Inc (NASDAQ:MBOT) stands ...

H.C. Wainwright's valuation of Microbot Medical (NASDAQ: MBOT) stands at an estimated market value of $255 million, or $9 per share, which underpins the revised price target. The current market ...